Drug Details

General Information of the Drug (ID: DR1194)
Name
Octyl disulfamate
Disease Breast cancer [ICD-11: 2C60] Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          3-O-acetylbetulin      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [1]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation		 Enhancement DNA damage
Enhancement Radiosensitivity
                    In-vitro Model MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
MDA-231 Breast cancer Homo sapiens
                    Experimental
                    Result(s)		 The combined treatment with 3-AC and CAI strongly enhanced radiosensitivity, increased cytotoxicity, inhibited cell motility and enhanced DNA damage.
Target and Pathway
Target(s) V-set and transmembrane domain-containing 1 (VSTM1)  Molecule Info  [2]
References
Reference 1 Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells. Chem Biol Interact. 2021 Jan 5;333:109326.
Reference 2 Synergistic antitumor activity of triple-regulated oncolytic adenovirus with VSTM1 and daunorubicin in leukemic cells. Apoptosis. 2016 Oct;21(10):1179-90.
 Download Picture         KEGG Link